Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
Doaa Ali AbdelmonsifAhmed S SultanWessam F El-HadidyDina Mohamed AbdallahPublished in: Molecular diagnosis & therapy (2018)
Targeting AMPK, mTOR and β-catenin by combined metformin/aspirin treatment could be a promising therapeutic strategy for Egyptian HCC patients, and possibly other HCC patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- cell proliferation
- low dose
- skeletal muscle
- type diabetes
- stem cells
- cardiovascular disease
- patient reported outcomes
- signaling pathway
- drug delivery
- cancer therapy
- mesenchymal stem cells
- patient reported
- protein kinase